吞噬作用屏蔽型慢病毒载体改善非人灵长类肝脏基因治疗
研究利用活体显微镜和慢病毒载体表面工程,发现将人类吞噬作用抑制因子CD47整合到载体细胞膜可保护慢病毒载体免受专职吞噬细胞摄取和先天免疫识别,从而促进其经全身给药后向肝细胞分布。通过提高CD47表面含量制备的吞噬作用屏蔽型慢病毒载体在非人灵长类静脉给药后,与亲本载体相比显示出选择性肝脾靶向和增强的肝细胞基因转移,达到转基因编码的人凝血因子IX的超生理活性,且无毒性迹象或转导细胞克隆扩增。
要点
- CD47整合到慢病毒载体细胞膜可保护其免受吞噬细胞摄取和先天免疫识别。
- 高CD47表面含量的吞噬作用屏蔽型慢病毒载体在非人灵长类中实现选择性肝脾靶向。
- 该载体增强肝细胞基因转移,达到人凝血因子IX超生理活性,无毒性或克隆扩增迹象。
核心结论
- 吞噬作用屏蔽型慢病毒载体经静脉给药至非人灵长类后,与亲本慢病毒载体相比,显示出选择性肝脾靶向和增强的肝细胞基因转移,达到人凝血因子IX的超生理活性,且无毒性迹象或转导细胞克隆扩增。
研究设计与样本
- 研究利用活体显微镜和慢病毒载体表面工程,在非人灵长类中经静脉给药评估吞噬作用屏蔽型慢病毒载体的靶向性和基因转移效果。
主要发现
- 人类吞噬作用抑制因子CD47整合到慢病毒载体细胞膜,在保护慢病毒载体免受专职吞噬细胞摄取和先天免疫识别中起主要作用,有利于全身给药后向肝细胞分布。
- 通过提高CD47表面含量制备的吞噬作用屏蔽型慢病毒载体,经静脉给药至非人灵长类后,与亲本慢病毒载体相比,显示出选择性肝脾靶向和增强的肝细胞基因转移。
- 该载体达到转基因编码的人凝血因子IX的超生理活性,且无毒性迹象或转导细胞克隆扩增。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver-directed gene therapy for the coagulation disorder hemophilia showed safe and effective results in clinical trials using adeno-associated viral vectors to replace a functional coagulation factor, although some unmet needs remain. Lentiviral vectors (LVs) may address some of these hurdles because of their potential for stable expression and the low prevalence of preexisting viral immunity in humans. However, systemic LV administration to hemophilic dogs was associated to mild acute toxicity and low efficacy at the administered doses. Here, exploiting intravital microscopy and LV surface engineering, we report a major role of the human phagocytosis inhibitor CD47, incorporated into LV cell membrane, in protecting LVs from uptake by professional phagocytes and innate immune sensing, thus favoring biodistribution to hepatocytes after systemic administration. By enforcing high CD47 surface content, we generated phagocytosis-shielded LVs which, upon intravenous administration to nonhuman primates, showed selective liver and spleen targeting and enhanced hepatocyte gene transfer compared to parental LV, reaching supraphysiological activity of human coagulation factor IX, the protein encoded by the transgene, without signs of toxicity or clonal expansion of transduced cells.
引用
- Milani M, Annoni A, Moalli F, et al. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci Transl Med. 2019. PMID: 31118293. doi:10.1126/scitranslmed.aav7325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。